Table 2. Clinical parameters and VITT... | American Society of Hematology

Table 2.

Clinical parameters and VITT diagnostic results of VITT-negative samples

Patient	Platelet nadir (×10⁹/L)	Clinical symptoms	Symptoms onset (no. of days after vaccination)	Anti-PF4-heparin IgG ELISA (OD)*	PF4-dependent platelet-activation assay (activated cells)†	IvIgG prior blood withdrawal	MAIPA‡
Patient	Platelet nadir (×10⁹/L)	Clinical symptoms	Symptoms onset (no. of days after vaccination)	Anti-PF4-heparin IgG ELISA (OD)*	PF4-dependent platelet-activation assay (activated cells)†	IvIgG prior blood withdrawal	GPIIb/IIIa antibodies	GPIb/IX antibodies	GPIa/IIa antibodies
Male, 30 y	110	Petechia, known primary sclerosing cholangitis	2	0.23	Negative	No	0.78	2.105	2.195
Male, 62 y	111	Thrombosis (site of thrombosis not indicated)	14	0.15	Negative	Yes	0.21	0.17	0.355
Female, 30 y	55	Initially with headache, fever, limb pain and flu-like syndroms; elevated d-dimer level	1	0.14	Negative	No	0.08	0.515	0.105
Female, 73 y	30	Not indicated	17	0.35	Negative	No	0.52	0.9	0.895
Male, 59 y	17	Gastric mucosal bleeding	45	0.44	Negative	Yes	0.23	0.29	0.36
Male, 78 y	4	Petechia, epistaxis	20	0.38	Negative	Yes	1.145	0.52	0.65
Male, 69 y	5	Petechia and oral bleeding, discomfort	Not known	0.1	Negative	No	0.555	0.865	0.385
Male, 71 y	2	Not known	10	0.1	Negative	Not known	0.665	1.28	0.75
Female, 21 y	13	Petechia, hematoma	∼21	0.27	Negative	Not known	0.215	0.185	0.25
Male, 62 y	5	Petechia	15	0.34	Negative	Yes	0.21	0.245	0.325
Female, 70 y	110	Not known	Not known	0.26	Negative	Not known	0.09	0.145	1.535

Patient	Platelet nadir (×10⁹/L)	Clinical symptoms	Symptoms onset (no. of days after vaccination)	Anti-PF4-heparin IgG ELISA (OD)*	PF4-dependent platelet-activation assay (activated cells)†	IvIgG prior blood withdrawal	MAIPA‡
Patient	Platelet nadir (×10⁹/L)	Clinical symptoms	Symptoms onset (no. of days after vaccination)	Anti-PF4-heparin IgG ELISA (OD)*	PF4-dependent platelet-activation assay (activated cells)†	IvIgG prior blood withdrawal	GPIIb/IIIa antibodies	GPIb/IX antibodies	GPIa/IIa antibodies
Male, 30 y	110	Petechia, known primary sclerosing cholangitis	2	0.23	Negative	No	0.78	2.105	2.195
Male, 62 y	111	Thrombosis (site of thrombosis not indicated)	14	0.15	Negative	Yes	0.21	0.17	0.355
Female, 30 y	55	Initially with headache, fever, limb pain and flu-like syndroms; elevated d-dimer level	1	0.14	Negative	No	0.08	0.515	0.105
Female, 73 y	30	Not indicated	17	0.35	Negative	No	0.52	0.9	0.895
Male, 59 y	17	Gastric mucosal bleeding	45	0.44	Negative	Yes	0.23	0.29	0.36
Male, 78 y	4	Petechia, epistaxis	20	0.38	Negative	Yes	1.145	0.52	0.65
Male, 69 y	5	Petechia and oral bleeding, discomfort	Not known	0.1	Negative	No	0.555	0.865	0.385
Male, 71 y	2	Not known	10	0.1	Negative	Not known	0.665	1.28	0.75
Female, 21 y	13	Petechia, hematoma	∼21	0.27	Negative	Not known	0.215	0.185	0.25
Male, 62 y	5	Petechia	15	0.34	Negative	Yes	0.21	0.245	0.325
Female, 70 y	110	Not known	Not known	0.26	Negative	Not known	0.09	0.145	1.535

PF4–heparin enzyme-linked immunosorbent assay (ELISA) was done as described by Juhl et al.²⁷ Reactivity on ELISA was defined according to the optical-density units (reference value OD < 0.50).

†

PF4-dependent platelet-activation assay was performed as recently described by Greinacher et al.⁴⁹ The cutoff for a negative result is 0.50 optical-density units.

‡

The cutoff for a negative result is OD < 0.2. Italic entries represent antiplatelet antibody detection.

View Large

This Feature Is Available To Subscribers Only